Background: Given the lack of a licensed product (LP), extemporaneous caffeine citrate (ECC) has been used by many hospital pharmacies. Objectives: Since July 2011, an LP has been available in Germany. We prospectively compared the safety profile of ECC and LP in preterm infants with apnea of prematurity. Methods: Between April 2010 and April 2013, selected side effects occurring with ECC or LP were documented in 6 German NICUs for infants ≤34 weeks' gestation using a longitudinal study design. The software developed for daily prescriptions in NICU residents requires entries if any of the following symptoms occurred during the last 24 h: tachycardia (resting heart rate >200/min), clinical or encephalographic seizures, gastric residuals, vomiting, or necrotizing enterocolitis (NEC). ECC and LP were administered at identical doses (20 mg/kg/day loading, 5-10 mg/kg/day maintenance) and in similar formulations either orally or intravenously. Results: 562 infants with 14,590 treatment days on ECC and 538 infants with 12,813 treatment days on LP were evaluated. The mean gestational age was similar (29.20 weeks for ECC vs. 29.14 weeks for LP). No relevant differences were seen concerning tachycardia, gastric residuals, or vomiting, but ECC was associated with a higher risk of NEC (risk ratio: 2.68, 95% CI: 1.01-7.23, p = 0.047) and, albeit not significantly so, seizures (risk ratio: 1.91, 95% CI: 0.53-6.96, p = 0.35). Conclusion: This survey demonstrates a similar safety profile for both forms of caffeine citrate. The lower NEC and seizure rate seen with the LP is intriguing, but requires confirmation in a controlled study design.

Keywords:
Caffeine citrate, Side effects, Tachycardia, Necrotizing enterocolitis, Seizures, Premature infant
1.
Miettinen O, Nurminen N: Comparative analysis of two rates. Statistics Med 1985;4:213-226.
2.
Clark RH, Bloom BT, Spitzer AR, Gerstmann DR: Reported medication use in the neonatal intensive care unit: data from a large national data set. Pediatrics 2006;117:1979-1987.
3.
Saliba E, Autret E, Gold F, Bloc D, Pourcelot L, Laugier J: Effect of caffeine on cerebral blood flow velocity in preterm infants. Biol Neonate 1989;56:198-203.
4.
Scanlon JE, Chin KC, Morgan ME, Durbin GM, Hale KA, Brown SS: Caffeine or theophylline for neonatal apnoea? Arch Dis Child 1992;67:425-428.
5.
Rennie JM, Roberton NRC: Textbook of Neonatology, vol 3. Edinburgh, Churchill Livingstone, 1999.
6.
Davis JM, Metrakos K, Aranda JV: Apnoea and seizures. Arch Dis Child 1986;61:791-793.
7.
van Rooij LG, van den Broek MP, Rademaker CM, de Vries LS: Clinical management of seizures in newborns: diagnosis and treatment. Paediatr Drugs 2013;15:9-18.
8.
Sheth RD, Hobbs GR, Mullett M: Neonatal seizures: incidence, onset, and etiology by gestational age. J Perinatol 1999;19:40-43.
9.
Pisani F, Copioli C, Turco EC, Sisti L, Cossu G, Seri S: Mortality risk after neonatal seizures in very preterm newborns. J Child Neurol 2012;27:1264-1269.
10.
Kosloske AM: Epidemiology of necrotizing enterocolitis. Acta Paediatr Suppl 1994;396:2-7.
11.
Guillet R, Stoll BJ, Cotten CM, Gantz M, McDonald S, Poole WK, et al: Association of H2-blocker therapy and higher incidence of necrotizing enterocolitis in very low birth weight infants. Pediatrics 2006;117:e137-e142.
12.
Uauy RD, Fanaroff AA, Korones SB, Phillips EA, Phillips JB, Wright LL: Necrotizing enterocolitis in very low birth weight infants: biodemographic and clinical correlates. National Institute of Child Health and Human Development Neonatal Research Network. J Pediatr 1991;119:630-638.
13.
Lampkin SJ, Turner AM, Lakshminrusimha S, Mathew B, Brown J, Fominaya CE, et al: Association between caffeine citrate exposure and necrotizing enterocolitis in preterm infants. Am J Health Syst Pharm 2013;70:603-608.
14.
Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, et al: Caffeine therapy for apnea of prematurity. N Engl J Med 2006;354:2112-2121.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.